What's Holding Back Type 1 Diabetes Screening in Canada?

Identifying Type 1 diabetes risk before diagnosis offers real benefits. Early detection can reduce the risk of diabetic ketoacidosis—a dangerous complication that sometimes appears when Type 1 is first diagnosed—and disease-modifying therapies can delay disease onset in people identified as at-risk.

For years, Canadian screening efforts have focused on first-degree relatives—siblings and children of people with Type 1. Now, researchers are exploring whether broader, population-wide screening could catch more people at risk, earlier.

The Canadian Population Screening for Risk of Type 1 Diabetes (CanScreen T1D) initiative conducted a national needs assessment to understand whether Canadian clinics and hospitals are ready to support a wider screening effort. Researchers surveyed institutional capacity and interviewed clinicians about their ability to provide follow-up care, run clinical trials, and deliver immunotherapies.

Eighteen institutions responded (a 39% response rate), revealing substantial differences across the country. Most institutions reported moderate to high capacity to care for people newly diagnosed with Type 1 diabetes. However, fewer reported they had sufficient capacity to support at-risk individuals or participate in prevention trials—the very services that would be needed if screening expands.

Interviews with clinicians uncovered concrete obstacles. Limited clinic space and staffing shortages emerged as major barriers. Even institutions with expertise and willingness to participate in screening programs lack the physical and human resources to expand care.

These gaps matter because identifying more at-risk individuals only works if there are enough trained staff and facilities to follow them, monitor their progress, and deliver preventive treatments when needed.

Despite the infrastructure challenges, participants broadly supported the idea of population-based screening for Type 1 diabetes risk. The appetite for screening exists among Canadian clinicians. The challenge is building the systems to make it work.

Closing the gap between support and capacity will require investment in staffing, clinic resources, and training—steps that are essential before a national screening program can scale up beyond current efforts focused on family members.

Source: Canadian journal of diabetes. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.